Benchmark Maintains Buy on Insulet, Lowers Price Target to $185
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Benchmark analyst Bruce D. Jackson maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $185.
Benchmark analyst Bruce D. Jackson maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $185.